Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. On last Friday Analyst firm HC Wainwright boosted its $90 price target to $120 for Arena Pharmaceuticals stock. If ARNA was to rally to this level, it would be a gain of more than 75%.
Analysts Believe This Stock Has 75% Potential Upside – ARNA stock #shorts
